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Abstract
Background:  Delirium increases morbidity, mortality and healthcare costs especially in the
elderly. Serum anticholinergic activity (SAA) is a suggested biomarker for anticholinergic burden
and delirium risk, but the association with cerebral cholinergic function remains unclear. To clarify
this relationship, we prospectively assessed the correlation of SAA with quantitative
electroencephalography (qEEG) power, delirium occurrence, functional and cognitive measures in
a cross-sectional sample of acutely hospitalized elderly (> 80 y) with high dementia and delirium
prevalence.
Methods: 61 consecutively admitted patients over 80 years underwent an extensive clinical and
neuropsychological evaluation. SAA was determined by using radio receptor assay as developed by
Tune, and standard as well as quantitative EEGs were obtained.
Results: 15 patients had dementia with additional delirium (DD) according to expert consensus
using DSM-IV criteria, 31 suffered from dementia without delirium (D), 15 were cognitively
unimpaired (CU). SAA was clearly detectable in all patients but one (mean 10.9 ± 7.1 pmol/ml), but
was not associated with expert-panel approved delirium diagnosis or cognitive functions. Delirium-
associated EEG abnormalities included occipital slowing, peak power and alpha decrease, delta and
theta power increase and slow wave ratio increase during active delirious states. EEG measures
correlated significantly with cognitive performance and delirium severity, but not with SAA levels.
Conclusion: In elderly with acute disease, EEG parameters reliable indicate delirium, but SAA
does not seem to reflect cerebral cholinergic function as measured by EEG and is not related to
delirium diagnosis.
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Background
Additive long lasting anticholinergic side effects of com-
monly prescribed drugs have recently gained special inter-
est in neuro-geriatric medicine. They are considered one
of the main reasons for cognitive decline [1] and delirium
in the elderly. Although delirium is a common cause of
morbidity and even mortality in the frail elderly and by
this has an enormous impact on health economy as well
as on individual quality of life, it remains under-diag-
nosed in elderly patients and especially in concomitant
dementia [2]. Multiple causes underlie confusional states,
resulting in a common final pathway of probably stress
induced neurotransmission imbalances with a predomi-
nant cholinergic deficit [2,3]. Frail elderly are especially at
risk because of multimorbidity, polypharmacy, accumu-
lated cerebral pathology and physiological age-related
changes. The concept of an anticholinergic burden has
been established to highlight overall anticholinergic med-
ication effects that could worsen the often impaired cog-
nitive performance in the elderly, and to mark delirium
risk
The anticholinergic burden has been identified using two
different approaches.
The first one combines pharmacological knowledge and
clinical experience to evaluate the overall central anti-
cholinergic load. [1,4,5] However, mainly peripheral anti-
cholinergic symptoms are screened. The second approach
measures the cumulative anticholinergic activity in the
peripheral blood utilizing a radio receptor assay devel-
oped by Tune in 1980 [6]. This assay detects muscarinic
anticholinergic activity in serum samples in comparison
to atropine. It has been used to detect global muscarinic
anticholinergic properties of various medications [7] and
to approve interventions for reducing the anticholinergic
burden [8]. Some authors (see [9] for review) found an
association of SAA and delirium in various settings, i.e.
surgical, ICU- and medical patients [10-12], while some
opposing findings exist in oldest old nursing home
patients [13]. Cognitive impairment or lower MMSE was
associated with higher SAA especially in dementia
[9,14,15], depression [16] and community-dwelled eld-
erly [17] but diverging results have also been reported
[14,18,19]. It has been presupposed, that this serum assay
also reflects the central situation, but this assumption is
unproven and has often been questioned [1,20,21]. The
CSF-serum-correlation of anticholinergic activity was only
reported in two small samples of younger presurgical
patients premedicated with central anticholinergics like
scopolamine or midazolam [22,23].
The EEG reflects summation potentials of cortical electric
activity, modulated by subcortical structures, in an unsur-
passed high temporal resolution. The basic EEG alpha
rhythm is modulated by cholinergic thalamo-cortical
pathways responsible for attention, alertness and vigi-
lance regulation. Inactivity of the arousal system causes a
rise of slow activity due to glial influences[24]. Centrally
acting anticholinergics such as scopolamine result in
occipital rhythm slowing, slow wave increase and
decrease of fast activity [25-27], a pattern very similar to
the EEG findings in delirium. Because of this distinct pat-
tern, the EEG is still regarded as the gold standard of delir-
ium diagnosis. [26,28] Especially quantitative EEG
(qEEG) evaluation has the potential to detect disease- and
pharmaco-related powerdensity changes in the different
frequency bands [28,29] even in the elderly with and
without concomitant dementia.[30,31]
Here we present a cross-sectional and prospective study
which aims to investigate the association of anticholiner-
gic burden assessments and EEG parameter in a patient
group with high delirium risk: the oldest old suffering
acute medical diseases and dementia. We assessed sub-
groups of these patients including cognitively unimpaired
elderly, patients with dementia and patients with addi-
tional delirum. We hypothesized that SAA measurement
correlates (i) with routine EEG (rEEG) and quantitative
EEG (qEEG) parameters and (ii) with functional and cog-
nitive measures. If so SAA would indicate the central
cholinergic transmission and would be suitable for the
use in delirium screening or prevention as has been rec-
ommended[32,33].
Methods
Subjects
All patients older than 80 years and admitted to the Uni-
versity of Heidelberg Geriatric Centre, Bethanien Hospi-
tal, on Tuesdays and Fridays for the treatment of an acute
disease were consecutively recruited between October
2003 and May 2004. 61 patients and, when appropriate,
their legal guardians gave written informed consent. The
study was conducted in accordance with the Declaration
of Helsinki and was approved by the university's ethics
review board (No.255/2003). All study examinations
were conducted on the third day after admission within a
4 hour time frame to limit fluctuation differences. Data
evaluation included age, Barthel Index[34] at admission
and discharge, length of hospital stay, delirium associated
factors (anemia, cachexia, dehydration, acute infections,
oxygen saturation, metabolic disturbances, diabetes mel-
litus, sensory impairment), the number of medications,
number of potentially anticholinergic, "delirogenic" med-
ication (corticoids, antibiotics, psychotropic medication,
furosemide [7]) and relevant diseases summarized by the
Cumulative Illness Rating Scale (CIRS)[35] (see table 1).BMC Neuroscience 2008, 9:86 http://www.biomedcentral.com/1471-2202/9/86
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Clinical and neuropsychological assessment
A consensus panel, consisting of a geriatric psychiatrist
and neurologist and a geriatric medicine specialist, pro-
vided diagnosis according DSM-IV criteria. Confusion
Assessment Method (CAM)[36,37] was used as a screen-
ing tool and diagnosis was based on patient's history, neu-
ropsychological testing, a focused caregiver's interview
and the Informed Questionnaire on Cognitive Decline of
the Elderly (IQCODE)[38] to ensure diagnostic quality of
dementia also. Neuropsychological testing included Mini
Mental State Examination (MMSE)[39] and the Short
Portable Mental Status Questionnaire (SPMSQ)[40].
Delirium severity was judged by the Delirium Index
(DI)[41] The patients were assigned to the following
groups according to DSMIV criteria for dementia and
delirium: Patients with delirium and dementia (DD) (n
= 15), demented patients without delirium (D) (n = 31)
and cognitively unimpaired (CU) (n = 15).
SAA Measurements
Venous blood was collected 1 hour before EEG recording
and immediately stored at 4°C for 1 hour until centrifu-
gation (7.000 rpm, 10 min). The supernatant was stored
at -80°C until SAA levels were determined. We used the
radio receptor assay developed by Tune et al [6] where
anticholinergic agents in patients' serum compete with tri-
tiated quinuclidinyl benzilate for mACH-receptors
obtained from rat forebrain/striatum homogenate. The
displacement of 3H-QNB was used to quantify SAA in
comparison to an Atropine standard curve. Detection
limit was 0.5 pmol/ml, samples were assessed as one
batch. Intra-assay accuracy was always between 93 and
109%, intra-assay precision was always better than 9%,
inter-assay accuracy ranged between 95 and 105% (5
spiked serum samples over 3 days at 5, 10, 25 and 50
pmol/ml).
EEG Procedures
EEGs were performed mornings in a shielded, quiet room
with artificial light with a computerized 32-channel EEG
(Nihon Kohden), 10–20 system including VEOG/HEOG,
linked C3C4 as reference, 500 Hz sampling rate, 0.03 Hz
and 70 Hz filter settings, impedance below 0.5 kOhm.
Patients' vigilance was optimized by using regular alerts
Table 1: Patient Group and Subgroup Description
(mean ± SD) Cognitively 
Unimpaired 
n = 15
Dementia 
n = 31
Delirium with 
Dementia 
n = 15
All patients 
n = 61
Statistics
Age 86.9 ± 4.0 86.3 ± 4.8 85.3 ± 4.6 86.2 ± 4.5 F(2,58) = 0,46; p = 0,44
CIRS 26.6 ± 4.8 30.5 ± 4.4 31.7 ± 5.5 29.9 ± 4.9 F(2,58) = 0,74; p = 0,48
Dementia type (n)
 AD/mixed/VaD
--- 19/9/3 61/29/
10%
9/5/1 60/33/7% 28/14/4 61/29/8% 
*
Medication amount
(Median, range)
5.1 ± 2.7
(5.0; 1–12)
5.3 ± 2.5
(5.0; 1–10)
5.7 ± 2.3
(6.0; 3–9)
5.4 ± 2.5
(5.0; 1–12)
F(2,58) = 0,23; p = 0,79
delirogenic 
medication
(Median, range)
1.6 ± 1.6
(1.0; 0–4)
1.8 ± 1.1
(2.0; 0–4)
2.5 ± 1.4
(2.0; 0–5)
1.9 ± 1.3
(2.0; 0–5)
F(2,58) = 0,20; p = 0,15
Acute Infection 1/7% 7/22% 3/20% 11/18% H (2,61) = 1.755; p = 0.42
days in hospital 20.5 ± 17.1 15.1 ± 6.8 18.1 ± 7.2 17.2 ± 10.4 F(2,58) = 1,43; p = 0,25
Barthel admission 62.5 ± 31.2 33.7 ± 24.3 45.0 ± 18.1 43.9 ± 27.2 F(2,52) = 6.17; p < 0.005 
CU >> D; CU > DD
-ADL discharge 75.8 ± 29.0 47.7 ± 31.7 61.7 ± 25.1 59.0 ± 31.2 F(2,44) = 3.78; p < 0.05 
CU > D
IQCODE (norm < 3.3) 3.1 ± 0.2 4.2 ± 0.6 4.2 ± 0.7 4.2 ± 0.7 F(2,43) = 3.93; p < 0.03 
CU < D, CU < DD
Delirium Index
(range 0 – 21)
2.5 ± 0.7 6.2 ± 4.0 8.7 ± 4.5 6.4 ± 1.1 H (2, 46) = 7,15 p =,028 
CU < D < DD
MMSE (norm > 28 P) 28.8 ± 1.8 16.7 ± 7.5 14.4 ± 6.0 19.1 ± 8.3 H (2,61) = 32.52; p < 0.001 
CU >> D; CU >> DD
SPMSQ (norm < 2) 0.6 ± 0.9 4.7 ± 2.8 6.4 ± 2.7 4.1 ± 3.2 H(2,60) = 27.24; p < 0.0001 
CU << D, CU << DD
SAA in pmol/ml 
(w/o extremes > 2SD)
9.33 ± 4.44
(9.33 ± 4.44)
11.03 ± 6.15
(10.27 ± 4.62)
12.25 ± 10.53
(9.77 ± 4.47)
10.91 ± 7.12
(9.91 ± 4.48)
F(2,57) = 0,71; p = 0,50
F(2,55) = 0,62; p = 0,54
Mean ± SD are shown. AD = Alzheimer Dementia, mixed = AD with vascular pathology, VaD = Vascular Dementia, SAA = Serum Anticholinergic 
Activity,. CIRS = Cumulative Illness Rating Scale, IQCODE = Informant Questionnaire on Cognitive Decline, SPMSQ = Short Portable Mental Status 
Questionnaire, MMSE = Mini Mental State Examination, Barthel-ADL = Activities of Daily Living. * n = 46 demented patients ANOVA/Kruskal-
Willis statistics and posthoc-testing, with < or > giving the direction of the difference at a significance level of p < 0.01; >> or << specifies direction 
at a higher significance level of p < 0.001BMC Neuroscience 2008, 9:86 http://www.biomedcentral.com/1471-2202/9/86
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(pencil knocking). For spectral analysis 50 artifact-free
epochs, each of 2 sec duration, were obtained (minute 5
to 8) in those EEGs without focal abnormalities (n = 49)
after semiautomatic artifact reduction, artifact detection
using EOG traces and manual removal. Routine EEG was
assessed according to clinical criteria by an experienced
neurophysiologist blinded to the patients' diagnoses.
Spectral analysis data (real and imaginary components)
were evaluated on rereferenced (average reference) EEG
using Brain Vision Analyzer software (BrainProducts
GmbH, Munich, Germany). FFT data for absolute (aPD)
and relative power density (rPD), normalized to 1–20 Hz,
were calculated for the parieto-occipital region (averaging
O1, O2, O9, O10, P3, P4, Pz, P7, P8) since EEG changes
in delirium are most prominent occipitally. AP peak
power and peak frequency as well as rPD in 2 Hz-fre-
quency bands (delta 1–3 Hz to alpha2 11–13 Hz) and an
aPD-slow wave ratio (A/TD = alpha1+alpha2/
theta1+theta2+delta) were obtained and Log10 trans-
formed to minimize skew and kurtosis.
Statistical analysis
Group differences were examined using univariate ANO-
VAs and Duncan's post-hoc-tests. EEG and log-trans-
formed qEEG variables were evaluated by repeated
measures ANOVAs (group*frequency bands) followed by
one-way ANOVAs for each variable separately or by
Kruskal-Wallis-ANOVAs. Pearson's correlation coeffi-
cients were calculated to evaluate the relation of descrip-
tive variables, EEG parameters and SAA. All statistics were
calculated using Statistica 6.0 StatSoft, Inc.
Results
The 61 elderly (86.2 ± 4.5 years, 74% female) had been
admitted because of acute infection (n = 11/18%), falls
(13/21%), cardiac or metabolic disease (9/15%), stroke
(5/8%), acute mental disorders (6/10%) and other medi-
cal conditions. Five EEG recordings could not be evalu-
ated because of technical artifacts.
Clinical Data
Subgroups did not differ with respect to age, number of
diagnoses, medication, delirium risk factors or so-called
delirogenic medication (table 1). Cognitive impairment
was reflected by MMSE and SPMSQ results (p < 0.001) as
well as proxies' IQCODE (p < 0.004). Cognitive impair-
ment was greatest in the delirium group. Delirium Index
(DI) demonstrated delirium severity (p < 0.02) No statis-
tical differences were revealed between the delirium plus
dementia (DD) and the sole dementia group (D) apart
from DI. MMSE and DI correlated in dementia (r = 0.89
and delirium plus dementia (r = 0.78). Cognitive impair-
ment correlated strongly with functional status and func-
tional outcome measured by Barthel-Index (r = 0.55; p <
0.005), but no significant correlations were detected with
medication amount, delirogenic medication or overall
disease severity (CIRS).
Serum anticholinergic activity
SAA samples were obtained in 60 patients. In one
demented patient no SAA activity could be detected. As
table 1 depicts, no differences in SAA-levels were found
between the three groups indicating that neither delirium
nor dementia is reflected. There was no significant corre-
lation between SAA levels and age, functional decline
(IQCODE), medication amount, delirogenic medication
use, delirium severity (DI) and overall disease severity
(CIRS). Analysis for the group as a whole yielded a modest
negative relation between cognitive performance and
anticholinergic burden (fig. 1a). Two patients, however,
showed extremely high SAA values (> 2SD) and were thus
excluded from further evaluation. An 82 year old woman
with admission diagnosis of anticholinergic delirium due
to amitryptiline medication had 47 pmol/ml; an 87 year
old male with acute pneumonia, fever, severe dementia
and 10 different medications, 4 of which had anticholin-
ergic properties, showed 33 pmol/ml. After their exclu-
sion, correlation with cognitive impairment (MMSE) was
no longer significant. Functional outcome was signifi-
cantly correlated with SAA (fig. 1b).
EEG results
Delirium cases revealed the highest amount of standard
EEG pathology, exhibiting occipital slowing (11/13),
theta and/or delta excess (11/13–85% resp. 9/13–69%),
insufficient or lost reactivity (13/13) and anteriorization
(11/13) in EEG, significantly different from CU (p <
0.01). Table 2 depicts significantly slowed EEG basic
rhythm in dementia and even more occipital slowing in
DD. QEEG showed significant delta and theta1 increase as
well as alpha decrease in DD, resulting in lower slow wave
ratio (A/TD) values compared to CU. In comparison to
demented patients without delirium, significant delta
increase and alpha2 decrease in DD were revealed.
Surprisingly, SAA levels did not correlate with any of the
EEG parameters (table 3). Thus, the typical EEG signs of
acute encephalopathy depicted in DD (delta increase,
alpha2 decrease, A/TD-ratio reduction) did not relate to
SAA levels. Also, EEG changes due to dementia as a
chronic encephalopathy (peak frequency slowing, theta1
increase) did not correlate with the anticholinergic bur-
den indicator in the group of D or DD (fig. 2).
In contrast, the aforementioned qEEG parameters corre-
lated with cognition (MMSE) (p < 0.005), revealing a neg-
ative correlation with slow wave bands, highest with
lower theta, and a positive correlation with alpha bands.
Similar correlations were found with the DI that under-BMC Neuroscience 2008, 9:86 http://www.biomedcentral.com/1471-2202/9/86
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Correlation between SAA and cognition and outcome Figure 1
Correlation between SAA and cognition and outcome. Only when extremes (Fig.1a: top, bottom right) were included 
into calculation, negative correlation with MMSE reached significance. Excluding extremes (bottom, Fig. 1b) reveals significant 
correlation with functional outcome.
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lined the association of EEG slowing and delirium sever-
ity. Functional outcome (Barthel-Index at discharge)
correlated highest with both alpha bands (p < 0.05) as is
depicted in table 3.
Discussion
In our prospective, cross-sectional study of SAA, which
has been proposed for delirium screening [7,33], we
detected substantial SAA levels in frail, often demented,
elderly. However, SAA levels revealed to be independent
of delirium and dementia diagnoses and did not correlate
with cognitive impairment. Nor did we find a correlation
with any rEEG or qEEG parameter known to be affected by
the central anticholinergic action of scopolamine [25,27],
and by delirium [26,28]. At least in oldest-old geriatric
inpatients, SAA levels do not seem to reflect the cerebral
situation as measured by clinical means and by EEG.
High SAA levels indicated a significant anticholinergic
burden detectable in the serum of all subgroups of frail
elderly with acute medical conditions, but were not
related to delirium and dementia diagnosis. SAA levels
reported in the literature were measured with comparable
methodology but revealed rather divergent levels [7,9],
presumably due to the different populations studied. Our
SAA levels of frail elderly were in line with those of other
investigations in comparable settings [8,10,14], though
some groups found much smaller SAA in quite similar
patients [9,11,12] especially in patients without delirium.
In our study, SAA levels did not differ in DD patients and
the D or CU subgroups which argues against the hypoth-
esis of a direct relation between delirium and SAA. The
two comparable studies reporting a significant SAA differ-
ence in delirium [10,12] exhibited several methodological
Table 2: Standard EEG and quantitative EEG parameters
Cognitively 
Unimpaired 
n = 13
Dementia 
N = 30 
(24)
Delirium with 
Dementia 
n = 13 (12)
Statistics
Background activity Hz
mean ± SD at rest
9.05 ± 0.67 7.67 ± 1.53 7.21 ± 1.12 F(2,54) = 7.60; p < 0.002;
CU >> D >> DD
aP-Peak frequency (Hz) 8.50 ± 0.84 7.27 ± 1.44 6.66 ± 1.13 F(2,46) = 7.30, p < 0.002;
CU >> D >> DD
A/TD-ratio 1.05 ± 1.10 0.60 ± 1.00 0.22 ± 1.18 F(2,46) = 7.84, p < 0.002;
CU > D >> DD;
rP-Delta μV2/Hz 1.21 ± 0.79 1.68 ± 0.79 2.51 ± 0.92 F(2,46) = 8.45, p < 0.001;
CU < D << DD;
rP-Theta1 μV2/Hz 0.62 ± 0.30 1.02 ± 0.44 1.14 ± 0.65 F(2,46) = 5.98, p < 0.005;
CU << D << DD
rP-Theta2 μV2/Hz 1.75 ± 9.6 1.77 ± 6.7 1.61 ± 0.55 F(2,46) = 0.20, p = 0.82
rP-Alpha1 μV2/Hz 2.08 ± 0.94 1.24 ± 0.76 0.86 ± 0.47 F(2,46) = 9.35, p < 0.0005;
CU >> D >> DD
rP-Alpha2 μV2/Hz 0.59 ± 0.29 0.49 ± 0.28 0.32 ± 0.15 F(2,46) = 4.72, p < 0.02;
CU >> DD; D > DD
Absolute Power(aP) values are given for Peak frequency and alpha/theta+delta ratio, frequency bands are given in relative powerdensity values, 
mean ± Standard deviation, ANOVA statistics and Duncan posthoc-testing, with < or > giving the direction of the difference at a significance level 
of p < 0.01; >> or << specifying direction at a higher significance level of p < 0.001.
Table 3: Correlations between QEEG and Cognition, Serum Anticholinergic Activity and Functional Outcome
aP-Peak frequency A/TD-ratio rP-Delta rP-Theta1 rP-Theta2 rP-Alpha1 rP-Alpha2
MMSE (n = 49) r = 0.53
p < 0,0001
r = 0.31
p = 0.027
r = -0.40
p = 0.004
r = -0.55
p = 0.000
r = 0.09
p = 0.526
r = 0.51
p < 0.0001
r = 0.37
p = 0.010
DI (n = 40) r = -0.46
p < 0,003
r = -0.32
p = 0.04
r = 0.22
p = 0.18
r = 0.49
p = 0.001
r = 0.09
p = 0.526
r = -0.36
p < 0.023
r = -0.26
p = 0.09
SAA (n = 47) r = 0.20
p = 0.171
r = 0.16
p = 0.280
r = 0.17
p = 0.242
r = 0.27
p = 0.067
r = -0.22
p = 0.137
r = 0.09
p = 0.538
r = 0.01
p = 0.98
BI-ADL admission (n = 45) r = 0.01
p = 0.96
r = -0.06
p = 0.684
r = -0.28
p = 0.065
r = -0.17
p = 0.256
r = 0.22
p = 0.146
r = 0.12
p = 0.437
r = 0.22
p = 0.148
BI-ADL Discharge (n = 38) r = 0.23
p = 0.174
r = 0.40
p = 0.012
r = -0.39
p = 0.016
r = -0.23
p = 0.172
r = -0.14
p = 0.404
r = 0.46
p = 0.004
r = 0.45
p = 0.004
Correlations are given for the whole group without extremes (n = 49). aP/rP = absolute/relative Power, SAA = Serum Anticholinergic Activity, BI-
ADL = Barthel Index, DI = Delirium Index; significant results are bold.BMC Neuroscience 2008, 9:86 http://www.biomedcentral.com/1471-2202/9/86
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Correlation between cognition, functional status and qEEG parameters Figure 2
Correlation between cognition, functional status and qEEG parameters.
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drawbacks. Delirium diagnosis in both studies was based
on screening instruments only, without psychiatric evalu-
ation; centrally acting anticholinergic drugs were signifi-
cantly more common with high SAA and delirium
[10,11]; outlier biases occurred [10] and infection was the
strongest delirium predictor. As in our study, SAA did not
correlate with definite anticholinergic drugs overall.[12]
Also, delirium itself did not correlate with an overall anti-
cholinergic burden but with specific centrally active drugs
[42]. Endogenous contributions to SAA, related to fever
and infection rather than delirium, and probably medi-
ated through stress mechanisms were recently
detected[13,22,43]. In animals, stress-induced hyperther-
mia was found to be modulated by a peripheral choliner-
gic mechanism [44]. It is therefore hypothesized that
stress- and fever related endogenous anticholinergic activ-
ity operates in the periphery [22].
In conclusion, SAA must be considered as a conglomerate
of anticholinergic properties of endogenous and exoge-
nous origin, which act on peripheral targets and only pos-
sibly on the CNS. Our results suggest, that SAA reflects
predominantly non-central-acting and medication-inde-
pendent components in frail oldest old with acute disease.
Typical EEG changes represent the gold standard of delir-
ium diagnosis[26,28,30] and our EEG results are in line
with these findings in delirium [28,31] and with dementia
studies [26,45]. REEG and qEEG parameters correlated
closely with delirium severity and cognitive impairment
underlining their relation to cholinergic activation.
EEG again confirms our expert panel based clinical sub-
group classification, but neither rEEG nor qEEG parame-
ters correlated with SAA levels. EEG patterns of centrally
acting anticholinergics such as scopolamine closely
resemble delirium changes in normal [25,27] and
demented subjects [46] while peripheral anticholinergics
do not exhibit EEG changes [27,29]. Thus, the lack of any
correlation of SAA with EEG parameters again gives strong
evidence that SAA in our sample of frail elderly does not
reflect the cerebral cholinergic situation. We confirmed
this recently in a younger sample of various ICU
patients[47], where SAA levels were found to be lower, but
also did not correlate to delirium and EEG measures.
In our frail elderly population no association was
observed between the anticholinergic burden and cogni-
tive deficits, not even in dementia. This finding is contrary
to previous studies describing an association of SAA with
lower MMSE [17,21,22], restricted in some to demented
patients [9,14], or to specific memory tests [16]. Others
reported no connection in non-demented elderly [14,19].
Reasons for these discrepancies include: Individual varia-
tions due to white matter load [21] and ApoE status [48],
which have been shown to influence cognitive perform-
ance and cognitive challenge recovery in non-demented
elderly. Dose-dependent influences of centrally acting
anticholinergics are also probable [14,22] and may have
been overlooked. In Chew's sample, e.g., most demented
subjects had received lorazepam [9], which was recently
reconfirmed by fMRT to impair memory [49] and facili-
tates delirium transition [50]. On the other hand, as
MMSE is a rather crude measure of memory functions,
slight differences might have been detectable with more
sophisticated tests on working memory and delayed recall
in our sample, as anticholinergic medication in general
has been proven to influence memory function in a sub-
tler way.[1,5]
However, we did find a moderate correlation of SAA with
functional outcome, indicating a negative influence of the
anticholinergic burden on functional capacity in D and in
acutely ill CU, supporting a former study [18]. In DD cor-
relation was lacking, indicating functional deficits caused
by additional mechanisms. Functional impairment may
be caused by peripheral side effects like accommodation
difficulties, brady- or tachycardia and gate distur-
bance.[20] On the other hand, peripheral cholinergic
pathways have also been described to influence memory
performance in mice [51], but this awaits confirmation in
humans.
Our study has several limitations. A larger sample size
might have clarified the correlation with the patients'
daily functions. Additionally, more extensive neuropsy-
chological assessment could evaluate specific but subtle
cognitive changes, e.g. memory disturbance. The addi-
tional assessment of CSF-AA with SAA and EEG parame-
ters would have strengthened conclusions regarding their
association. The correlation of CSF-AA and SAA with indi-
vidual substances and in different patient samples
remains to be assessed. Further studies on the central
pharmacodynamics of individual substances and on
blood-brain-barrier permeability in the elderly are
needed. Finally, our sample did not include delirium
patients without a prior cognitive decline. These patients
must be studied within a younger patient group with
lower dementia prevalence.
Conclusion
Our naturalistic cross-sectional study in frail elderly used
qEEG and thorough clinical delirium diagnosis (expert
consensus) to demonstrate for the first time that SAA lev-
els in frail elderly with acute medical conditions are not
delirium-related and therefore cannot be reliably applied
for delirium prevention or prediction in this relevant
group of patients. SAA seems to reflect primarily the
peripheral endogenous and exogenous anticholinergic
activity that, as animal research indicates, might alsoBMC Neuroscience 2008, 9:86 http://www.biomedcentral.com/1471-2202/9/86
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influence stress-induced thermoregulation and memory
performance. Delirium occurrence is, inter alia, depend-
ent on centrally acting anticholinergic mechanisms.
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